A Guilford-based business is touting a simple trick to avoid disruptions caused by President Donald Trump’s tariffs and trade negotiations: making all of their products in Maine.

Puritan Medical Products, a 500-employee business based in Piscataquis County, is expanding its workforce to meet the anticipated increase in demand for American-made medical supplies, the company announced Wednesday.

“There will be no tariff-related disruptions to the supply of Puritan swabs and other products,” said Bob Shultz, Puritan’s president and chief financial officer.

“Puritan remains bullish about the future and our ability to meet global demand for our many products,” said Shultz.

Central to the company’s messaging and branding is the idea that none of its medical products come from China — or any other nation that might see cost increases due to the quixotic application of tariffs coming from the White House.

The Maine-based manufacturer said it is experiencing the highest demand for its products since the height of the COVID-19 pandemic, when global supply chain disruptions saw the company emerge as a top producer of swabs and other medical products.

Founded in 1919, Puritan became a key player in pandemic response efforts after being tapped by the federal government to ramp up production of COVID-19 testing swabs. It quickly scaled its operations to produce up to 100 million swabs per month.

The company is now hiring for dozens of positions at its Guilford and Pittsfield plants to keep pace.

Puritan manufactures a wide array of sterile and non-sterile swabs used in healthcare, diagnostics, forensics and industry. Its swabs come in materials ranging from flocked fiber and rayon to cotton, polyester and foam.

The company, still family-owned, operates three manufacturing plants in Maine and a satellite office in Falmouth. Its leadership emphasized that all production is done domestically using U.S.-sourced materials — a rarity in today’s globalized economy.

Puritan said its long history of weathering economic uncertainty — from trade shifts to global health crises — positions it well for continued growth in 2025.

“This is not our first rodeo,” Shultz said. “Our success in the face of adversity continues to serve us well today.”